Enfusion (ENFN) reported Q3 adjusted net income Monday of $0.05 per diluted share, up from $0.04 a year earlier.
Analysts polled by Capital IQ expected $0.06.
Revenue for the quarter ended Sept. 30 was $51.2 million, up from $44.4 million a year earlier.
Analysts surveyed by Capital IQ expected $52.2 million.
For 2024, the company narrowed its revenue projection to between $202 million and $205 million, from a previous outlook of $200 million to $210 million. Analysts polled by Capital IQ expect $204.8 million.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。